KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions to authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Letter
- Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
- Guntram Schernthaner
- Diabetes Metab J. 2021;45(4):615-616. Published online July 30, 2021
- DOI: https://doi.org/10.4093/dmj.2021.0081
- 3,222 View
- 71 Download
- 2 Web of Science
- 2 Crossref
-
PDF
PubReader 
ePub -
Citations
Citations to this article as recorded by
- The risk of common hypoglycemic and antihypertensive medications and COVID-19: A 2-sample Mendelian randomization study
Ya Wang, Kai Li, Jiaxing Zeng, Shunyu Lu, Wangsheng Deng
Medicine.2024; 103(6): e36423. CrossRef - The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný, Guntram Schernthaner
Cardiovascular Diabetology.2021;[Epub] CrossRef
- The risk of common hypoglycemic and antihypertensive medications and COVID-19: A 2-sample Mendelian randomization study
First
Prev
